Tresiba (insulin degludec) has been in common use in Europe for some time, but was prevented from entering the United States by the FDA for several years. Now that it is available, Americans are discovering what Europeans already knew: it just plain works better for the majority of people. Smoother action, easier to manage . . . etc.